Malaria Prevention

Malaria is caused by 5 species of Plasmodium protozoa — P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi — transmitted through the bite of an infected female Anopheles mosquito, which feeds mainly between dusk and dawn.^[1] P. falciparum causes the most severe disease, including cerebral malaria, and can progress rapidly to death without prompt treatment; P. vivax and P. ovale form dormant liver-stage hypnozoites that can cause relapse months to years after the original exposure, even after a fully completed course of most chemoprophylaxis agents.^[2] No chemoprophylaxis regimen is completely protective and no malaria vaccine is licensed for routine traveller use in Canada, so prevention always combines a destination-appropriate drug regimen with rigorous mosquito-bite avoidance — and every traveller must understand that fever during or after travel to an endemic area is a medical emergency requiring urgent testing, not presumptive self-treatment.

Typical presentation

Fever is the cardinal symptom and may be accompanied by chills/rigors, headache, myalgia, fatigue, nausea, vomiting, or diarrhea — a presentation easily mistaken for a nonspecific viral illness or another travel-associated infection (dengue, typhoid, and traveller's diarrhea all overlap symptomatically). Malaria must always be actively tested for and excluded first in a febrile returned traveller given its potential lethality, regardless of what else is on the differential.^[1]

Classic cyclical fever patterns (every 48 or 72 hours) are unreliable, especially early in infection or in a partially immune or partially treated patient, so their absence never excludes malaria. Incubation is typically 7 days or more after the infective bite for P. falciparum (rarely under 6 days), but can be substantially longer for other species, and P. vivax/P. ovale hypnozoites can cause symptomatic relapse many months to several years after the traveller has left the endemic area and completed a full course of chemoprophylaxis — agents other than primaquine (and, where available, tafenoquine) do not eliminate this dormant liver stage.^[2]

• Travel to a malaria-endemic destination without pretravel consultation, or without chemoprophylaxis when it is indicated.
• Nonadherence to a prescribed chemoprophylaxis regimen, including stopping it early after returning home.
• Travel to West Africa or Oceania, which carry the highest transmission risk; travel to other parts of sub-Saharan Africa, South Asia, or South America, which carry intermediate risk.
• Visiting friends and relatives (VFR travellers) — this group is disproportionately affected, in part because pretravel consultation rates are lower and in part because partial immunity acquired in childhood wanes within a few years of leaving an endemic area and does not reliably protect against infection or severe disease on a return visit.
• Rural travel, travel during peak transmission season, and travel to lower-altitude areas within an endemic country, all of which raise risk compared with urban or high-altitude travel in the same country.
• Long-term travel or expatriate living in an endemic area, which raises cumulative exposure and the risk of running out of a reliable medication supply.
• Pregnancy, which increases both the likelihood of being bitten (Anopheles mosquitoes are more attracted to pregnant than nonpregnant people) and the severity of infection if it occurs.
• Young children, particularly under 5 years of age, who are at disproportionately higher risk of severe disease and death from P. falciparum malaria.
• Inconsistent or absent bite-prevention measures during exposure hours (dusk to dawn).

Pretravel risk assessment

Take a detailed itinerary — specific countries, regions or cities, dates of travel, urban versus rural exposure, elevation, and planned accommodations and activities — since malaria risk varies substantially within a single country and even within a single region by season.^[1]

Verify current destination-specific risk and resistance patterns against the Public Health Agency of Canada or CDC's country-by-country malaria pages before every trip, since risk areas and resistance patterns are revised periodically and are more precise than any static reference table.^[2]

Also collect: age and weight (for pediatric dosing), pregnancy/breastfeeding status, current medications and known drug interactions, seizure or psychiatric history, cardiac conduction history, renal function, known G6PD status, and drug allergies — all of these can change which chemoprophylaxis agent is appropriate.

Post-travel diagnostic testing

Thick and thin blood smear microscopy remains the reference standard: the thick smear is more sensitive for detecting parasites, and the thin smear allows species identification and quantification of parasite density, both of which guide treatment intensity and monitoring.^[4]

A rapid diagnostic test (RDT) can support same-day triage where microscopy is not immediately available, but does not replace microscopy for species confirmation and parasite density.

If the first test is negative but clinical suspicion remains, repeat smears at intervals over the next 48 hours rather than excluding malaria after a single negative result — early or low-density parasitemia can be missed on an initial smear.^[2]

When testing is not indicated

Routine pretravel or post-travel malaria testing in an asymptomatic traveller is not indicated — testing is reserved for travellers who develop fever or other compatible symptoms during or after travel.

• Accurately assess destination- and itinerary-specific malaria risk before every trip to an endemic area.
• Select an effective chemoprophylaxis regimen matched to the destination's resistance pattern and to the traveller's individual factors (pregnancy, age/weight, G6PD status, seizure/psychiatric history, renal function, drug interactions).
• Maximize protection against mosquito bites as a mandatory adjunct to, never a substitute for, chemoprophylaxis.
• Ensure travellers to remote areas have a standby emergency treatment plan when medical care will not be reachable within 24 hours of fever onset.
• Ensure every traveller understands that fever during or after travel is a medical emergency requiring immediate malaria testing.

Step 2 — select the agent by destination resistance pattern

Destination determines the resistance pattern, which determines which agents are appropriate for that trip:^[2]

Primaquine anti-relapse (terminal) therapy — a separate decision from primary chemoprophylaxis

Standby emergency self-treatment (SBET) — for remote travel only

Bite prevention is not optional — no chemoprophylaxis regimen is completely protective

Anopheles mosquitoes feed mainly between dusk and dawn, so protective measures matter most during these hours, though daytime protection is still worthwhile.^[3]

Insect repellents

Products registered in Canada containing 20-30% DEET or 20% icaridin (picaridin) are the preferred first-choice repellents and provide very high levels of protection against mosquito bites when used correctly and reapplied per label directions; p-menthane-3,8-diol (PMD, a synthetic derivative of oil of lemon eucalyptus) is a second-choice topical option for adults and children aged 3 years or older.^[3] See Drug Tables for the full age-based dosing table.

If sunscreen is also needed, apply sunscreen first and allow it to penetrate the skin for 10-15 minutes before applying repellent — combination sunscreen-DEET products are best avoided, since they may reduce sun protection and increase DEET skin absorption.^[3]

Bed nets and clothing

• Sleep under a bed net, preferably factory-treated with the insecticide permethrin, with proper tucking/installation.
• Most bed nets purchased in Canada have a shelf life of only about 6 months, while nets distributed in endemic countries last 3-5 years — do not rely on bringing a Canadian-purchased net for a long trip; a net sourced locally at the destination, or a long-lasting insecticide-treated net purchased for the purpose, lasts longer.^[3]
• Sleep in an air-conditioned or well-screened room whenever possible, and use screening on doors, windows, and eaves to keep mosquitoes out of accommodation and work areas.
• Wear full-length, loose-fitting, light-coloured clothing during peak biting hours, with sleeves rolled down and pant legs tucked into socks or boots.
• Permethrin-treated clothing adds meaningful additional protection, though no Health Canada-approved permethrin clothing-treatment product is currently available — commercially pre-treated clothing, or products obtained through a travel medicine clinic, are the practical options.

Measures that are not effective — do not recommend these

Electronic/ultrasonic devices, repellent-impregnated wristbands or ankle bands, electrocuting "bug zapper" devices, odour-baited traps, citronella plants, oral vitamin B1 supplements, and skin moisturizers that do not contain a recommended repellent active ingredient have not been shown to be effective against malaria-transmitting mosquitoes — do not substitute any of these for a registered topical repellent, treated bed net, or appropriate clothing.^[3]

Breastfeeding: antimalarial drug concentrations in breast milk are insufficient to protect a nursing infant, so a breastfed infant who needs chemoprophylaxis must still receive their own age/weight-appropriate dose. Hydroxychloroquine, mefloquine, and atovaquone-proguanil (for an infant weighing 5 kg or more) are all compatible with breastfeeding, as is doxycycline based on tetracycline-class breastfeeding data. Primaquine is contraindicated during breastfeeding unless both the breastfeeding parent and the infant have documented normal G6PD activity — the drug can be transferred through breast milk.^[7]

Pediatrics

Dose every agent by current body weight and reweigh for any extended trip, since a growing child's dose changes over time.^[8] Atovaquone-proguanil is used from 5 kg using the pediatric tablet strength (see Drug Tables for the full weight-band table). Mefloquine and hydroxychloroquine can be used at any age or weight per weight-based dosing. Doxycycline is contraindicated under age 8 for the duration required for chemoprophylaxis (typically well over 21 days once the pre-travel start and 4-week post-travel continuation are included) — it may still be used under age 8 specifically when the total course can be kept to 21 days or less and no other option is appropriate, reflecting current evidence that short courses do not cause the dental staining associated with prolonged use.^[6] Primaquine primary prophylaxis is generally reserved for children age 9 and older with confirmed normal G6PD activity, used only when first-line agents are inappropriate; consult a travel medicine or infectious disease specialist for pediatric primaquine use outside this age range.^[8] Tablets can be crushed and mixed with a strong-flavoured food (icing, peanut butter, jam, or infant formula) to mask taste — dispense a small surplus to cover a spat-out or vomited dose, with clear instructions on when a repeat dose is appropriate.

G6PD deficiency

Quantitative (or, where unavailable, qualitative) G6PD testing is mandatory before starting primaquine for any indication — primary prophylaxis or terminal anti-relapse therapy — since primaquine can precipitate severe, potentially life-threatening hemolytic anemia in a G6PD-deficient patient.^[2] Because G6PD deficiency is X-linked, female patients can be heterozygous with intermediate enzyme activity; a positive qualitative screen in a female traveller should prompt quantitative testing before a final decision, since a qualitative test alone may not reliably classify intermediate activity.^[2] Do not start primaquine in any patient with confirmed or unresolved G6PD deficiency — select an alternative agent instead. Tafenoquine, a single-dose alternative to primaquine used in the United States, carries the same G6PD hemolysis risk and mandatory testing requirement, but is not licensed or marketed in Canada and is not an option for Canadian-prescribed chemoprophylaxis.^[4]

Seizure and psychiatric history

Mefloquine is contraindicated in anyone with a seizure disorder, cardiac conduction abnormality, or a history of a serious psychiatric disorder — active depression, generalized anxiety disorder, psychosis, schizophrenia, or another major psychiatric illness — given the risk of neuropsychiatric and neurologic adverse reactions that can persist after the drug is stopped. Select atovaquone-proguanil or doxycycline instead for these patients.^[6]

Renal impairment

Atovaquone-proguanil is contraindicated in severe renal impairment (creatinine clearance under 30 mL/min) — use mefloquine or hydroxychloroquine instead, per the destination's resistance pattern. Review individual product information for dose adjustment of other agents in less severe renal impairment.

Reinforce adherence at every opportunity: give travellers a written reminder of exactly when to start, and — critically — exactly when to stop each agent after return, since post-return nonadherence (stopping early) is a common, preventable cause of prophylaxis failure.^[3] For a missed weekly dose (mefloquine, hydroxychloroquine) noticed within 1-2 days, take it immediately and resume the original weekly schedule; if more than 2 days late, take it immediately and resume weekly dosing from the new day. For a missed daily dose (atovaquone-proguanil, doxycycline, primaquine) noticed within 1-2 days, take it immediately and resume daily dosing from the new time — protective drug levels are less assured the longer a daily dose is delayed.^[4] Ask specifically about new neuropsychiatric symptoms (vivid dreams, insomnia, anxiety, low mood, dizziness) in anyone taking mefloquine, and switch to an alternative agent immediately if these occur, ideally before departure if the timeline allows. For a traveller on long-term hydroxychloroquine (cumulative dose exceeding 100 g chloroquine-base equivalent, or more than 5 years of continuous use), arrange retinal screening every 6-12 months. For atovaquone-proguanil co-prescribed with warfarin, monitor INR more closely, since proguanil can potentiate warfarin's anticoagulant effect. Document any G6PD test result in the patient's permanent record, since it remains valid for future primaquine (or other G6PD-relevant drug) decisions and does not need to be repeated.

1. Any fever during, or up to 1 year after, travel to a malaria-endemic area (especially within the first 3 months) requires urgent malaria testing — thick and thin blood smear plus, where available, a rapid diagnostic test — regardless of how carefully chemoprophylaxis was taken; no regimen is completely protective, and taking prophylaxis correctly never excludes the diagnosis.
2. If the first test is negative but clinical suspicion remains, repeat testing at intervals over the next 48 hours rather than reassuring the patient after a single negative result.
3. If malaria is confirmed, arrange immediate treatment, and for any severe-disease feature, immediate hospitalization — species-specific and severity-specific treatment is outside the scope of this prevention-focused chapter and needs infectious disease/travel medicine involvement; consider consultation through the Canadian Malaria Network for a complicated or severe case.
4. If a traveller develops intolerable adverse effects on chemoprophylaxis before or during travel (most often mefloquine neuropsychiatric symptoms), switch to a destination-appropriate alternative agent promptly rather than having the traveller simply stop chemoprophylaxis altogether.
5. If breakthrough fever occurs in a traveller who was genuinely adherent to chemoprophylaxis, treat this the same as item 1 — adherence does not rule out malaria, and reassurance based on adherence alone is a dangerous error.
6. Report every confirmed case to the relevant provincial or territorial public health authority — malaria is a reportable disease in Canada — and consider testing for co-infection or an alternative diagnosis if the clinical picture is atypical for the confirmed species.

• Assuming a traveller who grew up in or was born in an endemic area is protected by natural immunity — partial immunity wanes within a few years away and does not reliably prevent infection or severe disease.
• Prescribing or dispensing chloroquine, which is no longer commercially available in Canada — use hydroxychloroquine instead in chloroquine-sensitive destinations.
• Using atovaquone-proguanil in severe renal impairment (creatinine clearance under 30 mL/min) or in a traveller weighing under 5 kg.
• Starting mefloquine without asking about seizure history or a history of a serious psychiatric disorder.
• Stopping any blood-stage-only agent (doxycycline, mefloquine, hydroxychloroquine) before the full 4 weeks after leaving the endemic area — this is one of the most common preventable causes of prophylaxis failure.
• Starting primaquine — for primary prophylaxis or terminal anti-relapse therapy — without documented G6PD testing.
• Managing a returned traveller's fever presumptively, in either direction, without obtaining a blood smear or rapid test — malaria must be actively tested for and actively excluded, never assumed one way or the other.
• Excluding malaria on the basis of a single negative blood smear or rapid test when clinical suspicion remains.
• Forgetting to offer primaquine anti-relapse (terminal) therapy to an eligible long-term traveller or expatriate returning from a P. vivax/P. ovale-endemic area.
• Dispensing standby emergency treatment without a documented pretravel risk assessment, or choosing an SBET drug from the same class as the traveller's chemoprophylaxis agent.
• Treating chemoprophylaxis as sufficient on its own and de-emphasizing bite-prevention counselling.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Antifolate / naphthoquinone combination — chemoprophylaxis

Preferred first-line agent whenever several options are medically suitable for the destination and the traveller.

Tetracyclines — chemoprophylaxis

Quinoline derivatives — chemoprophylaxis

8-Aminoquinolines — special-situation chemoprophylaxis and anti-relapse therapy

Reserved for when other agents are contraindicated or not tolerated (primary prophylaxis), or added specifically to clear dormant liver hypnozoites (terminal anti-relapse therapy). Mandatory G6PD testing before any use.

Bite prevention — insect repellents and treated barriers

Mandatory adjunct to chemoprophylaxis, not an alternative to it. Health Canada-registered products only.